JNJ
JOHNSON & JOHNSON
NYSE · Healthcare · Drug Manufacturers - General · US
$253.79
−0.69%Jun 1, 2026, 02:03 UTC
Legend Biotech held an investor and analyst event to highlight long-term data and physician perspectives supporting broader use of CARVYKTI, its BCMA-directed CAR T-cell therapy for multiple myeloma.
Source:May 31, 2026, 13:00 UTC
Johnson & Johnson announced Phase 3 study results for ERLEADA (apalutamide) in prostate cancer, showing reduced risk of metastasis or death.
Source:May 31, 2026, 12:29 UTC
Johnson & Johnson announced pivotal results from the OrigAMI-4 study for RYBREVANT FASPRO in advanced head and neck cancer.
Source:
← PreviousPage 4